Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 11, 2017 - Issue
Submit an article Journal homepage
67
Views
17
CrossRef citations to date
0
Altmetric
Original Research

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines

Pengliang XinDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, China
,
Chuntuan LiDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, China
,
Yan ZhengDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, China
,
Qunyi PengDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, China
,
Huifang XiaoDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, China
,
Yuanling HuangDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, China
&
Xiongpeng ZhuDepartment of Haematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Licheng, Quanzhou, Fujian Province, ChinaCorrespondence[email protected]
 show all
Pages 1115-1126 | Published online: 03 Apr 2017

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sylwia Flis & Tomasz Chojnacki. (2019) Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Design, Development and Therapy 13, pages 825-843.
Read now
Pengliang Xin, Wenqian Xu, Xiongpeng Zhu, Chuntuan Li, Yan Zheng, Tingjin Zheng, Wenzhao Cheng & Qunyi Peng. (2019) Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia. Cancer Management and Research 11, pages 7933-7951.
Read now

Articles from other publishers (15)

You-lu Pan, Shen-xin Zeng, Rong-rong Hao, Mei-hao Liang, Zheng-rong Shen & Wen-hai Huang. (2022) The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. European Journal of Medicinal Chemistry 238, pages 114442.
Crossref
Wei Li, Yang Yu, Huanchen Cheng, Shengwei Liu, Tiejun Gong, Jun Ma & Qinghua Tang. (2022) Quercetin Inhibits KBM7R Cell Proliferation through Wnt/β-Catenin Signaling. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-7.
Crossref
Pei-Shan Wu, Chih-Yang Wang, Pin-Shern Chen, Jui-Hsiang Hung, Jui-Hung Yen & Ming-Jiuan Wu. (2021) 8-Hydroxydaidzein Downregulates JAK/STAT, MMP, Oxidative Phosphorylation, and PI3K/AKT Pathways in K562 Cells. Biomedicines 9:12, pages 1907.
Crossref
Hanieh Mojtahedi, Niloufar Yazdanpanah & Nima Rezaei. (2021) Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Research & Therapy 12:1.
Crossref
Cagla Kayabasi, Besra Ozmen Yelken, Aycan Asik, Tugce Balci Okcanoglu, Fatma Sogutlu, Roya Gasimli, Sunde Yilmaz Susluer, Guray Saydam, Cigir Biray Avci & Cumhur Gunduz. (2021) PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. European Journal of Pharmacology 910, pages 174446.
Crossref
Christian Boni & Claudio Sorio. (2021) Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia. Cancers 13:10, pages 2311.
Crossref
Mohammad Al Hamad. (2022) Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. F1000Research 10, pages 1288.
Crossref
Mohammad Al Hamad. (2021) Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. F1000Research 10, pages 1288.
Crossref
Priyanka Singh, Veerandra Kumar, Sonu Kumar Gupta, Gudia Kumari & Malkhey Verma. (2021) Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. Medical Oncology 38:1.
Crossref
Tuhina Khan, Nicola Relitti, Margherita Brindisi, Stefania Magnano, Daniela Zisterer, Sandra Gemma, Stefania Butini & Giuseppe Campiani. (2019) Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. Medicinal Research Reviews 40:3, pages 1002-1060.
Crossref
Maged. W. Helmy, Asser I. Ghoneim, Mohamed A. Katary & Rana K. Elmahdy. (2020) The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis. Molecular Biology Reports 47:3, pages 2217-2230.
Crossref
Zhenru Xu, Xu Han, Daming Ou, Ting Liu, Zunxiong Li, Guanmin Jiang, Jing Liu & Ji Zhang. (2019) Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Applied Microbiology and Biotechnology 104:2, pages 575-587.
Crossref
Jie Li, Wenjing Liu, Hongling Hao, Qiuyi Wang & Liying Xue. (2019) Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway. Oncology Letters.
Crossref
Marion Orsini, Franck Morceau, Mario Dicato & Marc Diederich. (2018) Autophagy as a pharmacological target in hematopoiesis and hematological disorders. Biochemical Pharmacology 152, pages 347-361.
Crossref
Cuicui Liu, Jiaqiang Xing & Yujun Gao. (2018) UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis. Thoracic Cancer 9:1, pages 105-111.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.